Ruth Tamara Valencia-Portillo

Ruth Tamara Valencia-Portillo

Auto-generated profile, based on publicly available information

Ruth Tamara Valencia-Portillo

Universidade de São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
MFMaria Marta Figueiredo
Maria Marta Figueiredo
ASAnna R. R. dos Santos
Anna R. R. dos Santos
LGLara Godoi
Lara Godoi
NCNatalia Salazar Castro
Natalia Salazar Castro
BABruno C. de Andrade
Bruno C. de Andrade
AFAna Paula Fernandes
Ana Paula Fernandes
Summary. Human visceral leishmaniasis (VL) is a major public health problem worldwide, leading to significant mortality rates if not properly treated and controlled. Precise identification of infected patients is essential to establish treatment and control measures. Although several VL serological diagnosis advances have been accomplished lately, mainly using recombinant antigens and immunochromatographic tests (ICTs), improvements may still be achieved using multiepitope chimeric proteins in different test platforms. Here, we reported on the evaluation of ELISA and an ICT developed with a new chimeric protein, named DTL-4, based on repetitive antigenic sequences, including those present in the A2 protein. Methods. A total of 1028 sera samples were used for the development and validation of ELISA (321 samples from L. infantum-infected patients, 62 samples from VL/AIDS coinfected patients, 236 samples from patients infected with other diseases, and 409 samples from healthy donors). A total of 520 sera samples were used to develop and validate ICT (249 samples from L. infantum-infected patients, 46 samples from VL/AIDS coinfected patients, 40 samples from patients infected with other diseases, and 185 samples from healthy donors). Findings. Using the validation sera panels, DTL-4-based ELISA displayed an overall sensitivity of 94.61 (95 CI: 89.94-97.28), a specificity of 99.41 (95 CI: 96.39-99.99), and an accuracy of 97.02 (95 CI: 94.61-98.38), while for ICT, sensitivity, specificity, and accuracy values corresponded to 91.98 (95 CI: 86.65-95.39), 100.00 (95 CI: 96.30-100.00), and 95.14 (95 CI: 91.62-97.15), respectively. When testing sera samples from VL/AIDS coinfected patients, DTL-4-ELISA displayed a sensitivity of 77.42 (95 CI: 65.48-86.16), a specificity of 99.41 (95 CI: 96.39-99.99), and an accuracy of 93.51 (95 CI: 89.49-96.10), while for DTL-4-ICT, sensitivity was 73.91 (95 CI: 59.74-84.40), specificity was 90.63 (95 CI: 81.02-95.63), and accuracy was 82.00 (95 CI: 73.63-90.91). Conclusion. DTL-4 is a promising candidate antigen for serodiagnosis of VL patients, including those with VL/AIDS coinfection, when incorporated into ELISA or ICT test formats.

2 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MFMahyumi Fujimori
Mahyumi Fujimori
RVRuth Tamara Valencia-Portillo
Ruth Tamara Valencia-Portillo
JLJosé Angelo Lauletta Lindoso
José Angelo Lauletta Lindoso
BCBeatriz Julieta Celeste
Beatriz Julieta Celeste
RARoque Pacheco de Almeida
Roque Pacheco de Almeida
MSMaria Carmen Arroyo Sanchez
Maria Carmen Arroyo Sanchez
In the Americas, visceral leishmaniasis (VL) is caused by the protozoan Leishmania infantum, leading to death if not promptly diagnosed and treated. In Brazil, the disease reaches all regions, and in 2020, 1,933 VL cases were reported with 9.5% lethality. Thus, an accurate diagnosis is essential to provide the appropriate treatment. Serological VL diagnosis is based mainly on immunochromatographic tests, but their performance may vary by location, and evaluation of diagnostic alternatives is necessary. In this study, we aimed to evaluate the performance of ELISA with the scantily studied recombinant antigens, K18 and KR95, comparing their performance with the already known rK28 and rK39. Sera from parasitologically confirmed symptomatic VL patients (n = 90) and healthy endemic controls (n = 90) were submitted to ELISA with rK18 and rKR95. Sensitivity (95% CI) was, respectively, 83.3% (74.2–89.7) and 95.6% (88.8–98.6), and specificity (95% CI) was 93.3% (85.9–97.2) and 97.8% (91.8–99.9). For validation of ELISA with the recombinant antigens, we included samples from 122 VL patients and 83 healthy controls collected in three regions in Brazil (Northeast, Southeast, and Midwest). When comparing the results obtained with the VL patients’ samples, significantly lower sensitivity was obtained by rK18-ELISA (88.5%, 95% CI: 81.5–93.2) compared with rK28-ELISA (95.9%, 95% CI: 90.5–98.5), but the sensitivity was similar comparing rKR95-ELISA (95.1%, 95% CI: 89.5–98.0), rK28-ELISA (95.9%, 95% CI: 90.5–98.5), and rK39-ELISA (94.3%, 95% CI: 88.4–97.4). Analyzing the specificity, it was lowest with rK18-ELISA (62.7%, 95% CI: 51.9–72.3) with 83 healthy control samples. Conversely, higher and similar specificity was obtained by rKR95-ELISA (96.4%, 95% CI: 89.5–99.2), rK28-ELISA (95.2%, 95% CI: 87.9–98.5), and rK39-ELISA (95.2%, 95% CI: 87.9–98.5). There was no difference in sensitivity and specificity across localities. Cross-reactivity assessment, performed with sera of patients diagnosed with inflammatory disorders and other infectious diseases, was 34.2% with rK18-ELISA and 3.1% with rKR95-ELISA. Based on these data, we suggest using recombinant antigen KR95 in serological assays for VL diagnosis.

15 August 2020 in Bionatura
Verified
Journal Article
Open access
RPRuth T. Valencia Portillo
Ruth T. Valencia Portillo
BUBernardina Amorín Uscata
Bernardina Amorín Uscata
FGFernando A Gonzales-Zubiate
Fernando A Gonzales-Zubiate
KMKatia Juscamaita Medina
Katia Juscamaita Medina
OSOrlando Sevillano
Orlando Sevillano
ESEduardo Milton Ramos Sanchez
Eduardo Milton Ramos Sanchez
La enfermedad respiratoria COVID-19 causada por el virus SARS-Cov-2 cuenta con más de 18 millones de personas infectadas y más de 600 mil muertes en el mundo, en Ecuador se tienen ya más de 88 mil infectados. Siendo el cuarto país con menos pruebas de diagnóstico realizadas, Ecuador podría afrontar un retraso en la investigación epidemiología y una ausencia de datos reales de la población afectada. Se cuenta con dos tipos de pruebas para el diagnóstico de SARS-CoV-2: las pruebas moleculares que son el Gold estándar y que se basan en la detección del virus (qRT-PCR y RT-LAMP) y las pruebas rápidas que detectan anticuerpos generados por la respuesta inmunológica del paciente. Ambas pruebas presentan pros y contras que las hacen complementarias y aumentan su alcance, ya que el foco poblacional es distinto. Las pruebas moleculares pueden detectar la presencia del virus en media, una semana antes y hasta una semana después de la aparición de los síntomas. Sin embargo, qué ocurre con los individuos asintomáticos que no fueron sometidos a ningún tipo de prueba diagnóstica y que ignoran si fueron infectados o no, y en qué momento fueron infectados. Para este grupo existen las pruebas rápidas, pruebas que detectan la respuesta inmunológica del individuo. Es así como las pruebas de diagnóstico se convierten en herramientas de vital importancia, complementando los estudios de los cuadros clínicos y la búsqueda activa de personas asintomáticas que ya pasaron del pico de carga viral. Inicialmente, la cuarentena controló el número de infectados pero la dinámica económica ha obligado a la población a salir de su hogar y es por esto que en este momento se necesitan nuevas estrategias para minimizar los efectos del SARS-CoV-2. En conclusión, las pruebas rápidas serían una solución que aceleraría la identificación y aislamiento de los individuos infectados, estimando con mayor exactitud el número de contagios, lo que permitiría una mejor toma de decisiones y el desarrollo de políticas públicas para contrarrestar la presente pandemia.

1 January 2025 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
GJGustavo Henrique Johanson
Gustavo Henrique Johanson
MSMaria Carmen Arroyo Sanchez
Maria Carmen Arroyo Sanchez
RSRegina Maia de Souza
Regina Maia de Souza
BCBeatriz Julieta Celeste
Beatriz Julieta Celeste
RVRuth Tamara Valencia-Portillo
Ruth Tamara Valencia-Portillo
VAValdir Sabbaga Amato
Valdir Sabbaga Amato
This study examines the prevalence of anti-Leishmania IgG antibodies and Leishmania spp. infections among Brazilian kidney transplant recipients and their living donors before and after transplantation. A total of 48 donor-recipient pairs were recruited from July 14, 2022, to December 18, 2023. ELISA was used to test donors and recipients with a crude antigen of Leishmania major-like (Lm-ELISA), along with recombinant Lb6H (rLb6H-ELISA) and K39 (rK39-ELISA). Additionally, PCR was used to test recipients. Of the 48 donors, 25 (52.1%, 95%CI: 38.3–65.5) tested positive with Lm-ELISA, 4 (8.3%, 95%CI: 2.8–20.1) with rLb6H-ELISA, and 2 (4.2%, 95%CI: 0.4–14.8) with rK39-ELISA. Before transplantation, 31 recipients (64.6%, 95%CI: 50.4–76.6) were positive with Lm-ELISA, 5 (10.4%, 95%CI: 4.1–22.6) with rLb6H-ELISA, 1 (2.1%, 95%CI: <0.01–11.9) with rK39-ELISA, and 2 (4.2%, 95%CI: 0.4–14.8) with PCR. At 365 days post-transplant, 35 recipients underwent serological and molecular testing. Of these, 14 (40.0%, 95%CI: 25.5–56.5) tested positive with Lm-ELISA, 4 (11.4%, 95%CI: 3.9–26.5) with rLb6H-ELISA, 0 (0.0%, 95%CI: 0.0–11.8) with rK39-ELISA, and 2 (5.7%, 95%CI: 0.6–19.6) with PCR. Combining serological and molecular methods showed promising potential for early detection and ongoing monitoring of leishmaniasis in kidney transplant recipients and their donors. These findings highlight the urgent need for regulatory measures to implement Leishmania-specific donor screening and recipient monitoring using PCR and targeted serological tests, as well as close observation of signs and symptoms of leishmaniasis.